RecruitingNot ApplicableNCT05872776
BEAT AF - Braking Ectopic Atrial Trends In Atrial Fibrillation
A Multi Center Randomized, Double Blinded, Sham Controlled, Clinical Study Aimed to Determine the Efficacy of CardiaCare™ RR2 Home-care Neuromodulation System in Reducing Atrial Fibrillation Burden and Symptoms in Paroxysmal AF Patients
Sponsor
Ziv HealthCare Ltd.
Enrollment
50 participants
Start Date
Feb 16, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
Paroxysmal AF subjects with a documented ECG event of AF will be recruited to the study To assess the efficacy of CardiaCare™ RR2 wearable home-care neuromodulation system in reducing AF burden and symptoms in Paroxysmal AF patients
Eligibility
Min Age: 18 YearsMax Age: 85 Years
Inclusion Criteria6
- Men and women ages 18-85 years with history of documented paroxysmal (\<7 days) atrial fibrillation
- AF Burden (% time in AF) of more than 0.5% and less than 25% as evident by a continuous 14 days ECG recording at baseline (at minimum 168 hours)
- Ability and willingness to sign an informed consent form
- Ability and willingness to use CardiaCare home care device and ECG chest patch and has an available smart phone
- Known symptomatic AF event over the recent 3 months
- Willing not to change the antiarrhythmic treatment
Exclusion Criteria17
- Hemodynamic instability (systolic blood pressure \<100mmHg or heart rate\>170 bpm at Baseline) during recruitment visit
- Known history or current diagnosis of atrial flutter
- An active myocardial infarction evident from ECG
- Recent stroke or myocardial infarction (\<6 months)
- History of sick sinus syndrome 2nd or 3rd degree AV block, bifascicular block or prolonged (PR\>300ms) 1st degree AV block
- Unilateral or bilateral vagotomy
- History of persistent AF with documented AF episodes of \>7 days
- Significant valvular disorder (i.e., prosthetic valve or hemodynamically relevant valvular diseases or valvular AF)
- History of Impaired systolic function with EF\<40 % or NY Class III or IV heart failure classification
- Dilatated left atria with a diameter \> 50mm as evident by an echocardiogram
- Currently enrolled in another study
- Recurrent vaso-vagal syncopal episodes
- Pregnancy or breast feeding
- Pacemaker or CRTD or any implanted electrical stimulating device
- History of epilepsy or seizures
- Peripheral neuropathy or dermatological condition affecting the tested upper extremity area
- Unsuitable for participating in the study according to attending physician
Interventions
DEVICENeuromodulation with RR2 device
non-invasive neuromodulation with RR2 device
DEVICEMock sham neuromodulation with sham RR2 device
Mock sham stimulation with RR2 device
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05872776
Related Trials
EXercise Cardiac Magnetic Resonance Assessment of Left Atrial Mechanics Following Ablation
NCT062127911 location
POLARx Post Approval Study (POLARx PAS)
NCT0617060611 locations
Evaluation of Novel Waveforms Delivered Using the FARAPULSE™ PFA System
NCT074443201 location
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
NCT071165256 locations
Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB)
NCT073449611 location